596 related articles for article (PubMed ID: 27460211)
1. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
Xin Y; Manson J; Govan L; Harbour R; Bennison J; Watson E; Wu O
BMC Gastroenterol; 2016 Jul; 16(1):80. PubMed ID: 27460211
[TBL] [Abstract][Full Text] [Related]
2. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
3. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
5. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
Buzás GM; Józan J
Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
[TBL] [Abstract][Full Text] [Related]
6. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Li Y; Huang X; Yao L; Shi R; Zhang G
Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
[TBL] [Abstract][Full Text] [Related]
7. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori treatment: Still a work in progress.
Senatore FJ; Wilmot J; Birk JW
Postgrad Med; 2016 Jan; 128(1):152-7. PubMed ID: 26490697
[TBL] [Abstract][Full Text] [Related]
11. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Niv Y
Digestion; 2016; 93(2):167-73. PubMed ID: 26849820
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.
Gisbert JP; Gonzalez L; Calvet X
Helicobacter; 2005 Jun; 10(3):157-71. PubMed ID: 15904473
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Helicobacter pylori infection: a clinical practice update.
Zagari RM; Frazzoni L; Marasco G; Fuccio L; Bazzoli F
Minerva Med; 2021 Apr; 112(2):281-287. PubMed ID: 32700868
[TBL] [Abstract][Full Text] [Related]
14. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Fallone CA; Moss SF; Malfertheiner P
Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990
[TBL] [Abstract][Full Text] [Related]
15. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Zhang M; Chen CY; Wang XT; Lyu B
Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
[No Abstract] [Full Text] [Related]
16. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
[TBL] [Abstract][Full Text] [Related]
18. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
19. Eradication Rate of
Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
[TBL] [Abstract][Full Text] [Related]
20. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection.
Buzás GM; Józan J
J Gastroenterol Hepatol; 2007 Oct; 22(10):1571-81. PubMed ID: 17845685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
